Top Page
Bioxyne Limited
(Sydney:BXN)
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Bioxyne Limited Business Overview & Revenue Model
Bioxyne Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 17.19M | 9.33M | 5.16M | 463.64K | 2.11M | 2.26M | Gross Profit |
| 6.82M | 1.71M | 343.13K | -224.10K | 639.71K | 638.94K | EBIT |
| 3.74M | -1.66M | -2.05M | -454.44K | -572.42K | -575.98K | EBITDA |
| 3.30M | -1.08M | -1.88M | -463.30K | -356.42K | -440.46K | Net Income Common Stockholders |
| 2.24M | -13.33M | -1.94M | -494.02K | -495.73K | -593.10K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.68M | 1.03M | 3.85M | 65.93K | 1.60M | 1.75M | Total Assets |
| 14.93M | 6.70M | 17.69M | 445.59K | 2.68M | 3.34M | Total Debt |
| 1.73M | 673.72K | 558.61K | 397.39K | 47.46K | 47.46K | Net Debt |
| -945.45K | -354.27K | -3.29M | 331.46K | -1.55M | -1.70M | Total Liabilities |
| 8.06M | 3.40M | 2.69M | 815.15K | 744.75K | 726.12K | Stockholders Equity |
| 7.20M | 3.61M | 15.14M | -364.84K | 1.88M | 2.56M |
| Cash Flow | Free Cash Flow | ||||
| 108.08K | -4.05M | -897.92K | -566.88K | 19.47K | 14.59K | Operating Cash Flow |
| 1.57M | -3.56M | -841.28K | -506.81K | 53.13K | 48.25K | Investing Cash Flow |
| -1.78M | -492.66K | 3.96M | 26.61K | -33.66K | -33.66K | Financing Cash Flow |
| 1.21M | 1.21M | 947.17K | 493.24K | -46.78K | -52.33K |
Bioxyne Limited Technical Analysis
Bioxyne Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
53 Neutral | AU$58.45M | 24.55 | 55.63% | ― | 98.57% | ― | |
50 Neutral | AU$676.58M | ― | -112.97% | ― | ― | -84.82% | |
43 Neutral | AU$37.28M | ― | -75.39% | ― | ― | 44.29% | |
36 Underperform | $2.65M | ― | -119.28% | ― | ― | 64.10% | |
34 Underperform | AU$2.93M | ― | -309.52% | ― | 73.53% | -7.35% |
Bioxyne Limited Corporate Events
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has entered the German cannabis market by securing a manufacture and supply agreement worth €3.2 million (A$5.6 million) with Farmakem d.o.o. and Adrex Pharmaceuticals GmbH. This agreement involves supplying a minimum of 1,600 kg of GMP-certified medical cannabis flower, with the first delivery scheduled for September 2025. The German medical cannabis market is rapidly growing, and Bioxyne’s entry is expected to bolster its growth in FY2026, leveraging its GMP certification for competitive advantages in Germany and other European markets.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has received GMP compliance certificates under Mutual Recognition Agreements with several countries, including the UK, Canada, and the EU. This certification supports Bioxyne’s strategy to expand its global presence, particularly in European markets, and positions the company for growth in FY2026 as it enters new high-growth markets such as the UK and Germany.
Bioxyne Limited is set to host a Business Update Webinar to discuss its FY2025 revenue guidance and market performance in Australia, the UK, and the EU. The company anticipates continued growth in FY2026, driven by its expansion into high-growth markets such as the UK and Germany. This strategic positioning is expected to enhance Bioxyne’s market presence and offer promising opportunities for stakeholders.
Bioxyne Limited has upgraded its full-year FY2025 revenue guidance to $28 million, reflecting significant growth driven by its Australian pharmaceutical manufacturing and supply operations. The company reported a 267% increase in revenue for the first half of FY2025 and anticipates continued expansion in FY2026, particularly in Australia, the UK, Germany, and other EU markets. Bioxyne’s subsidiary, Breathe Life Sciences, leads the Australian market in manufacturing medicinal cannabis, MDMA, and Psilocybin products, contributing to the company’s robust performance. The company is also advancing its MDMA capsules into commercial production, positioning itself for long-term success in the growing psychedelic drugs market.
Bioxyne Limited is hosting an online investor webinar to update shareholders and potential investors on the company’s progress and future plans. The event will feature a presentation by Managing Director Sam Watson, followed by a live Q&A session, allowing participants to engage directly with the company’s leadership.
Bioxyne Limited has appointed Professor Michael Barnes, a leading consultant neurologist and expert in medical cannabis, to its advisory board. This strategic move is expected to enhance Bioxyne’s operations in the UK medicinal cannabis market, leveraging Prof. Barnes’s extensive experience in medicine registration and distribution, which aligns with the company’s global expansion goals.
Bioxyne Limited has secured a $7 million manufacturing and supply agreement with NectarTek, an Australian healthcare company. This deal, which marks a 200% revenue increase from the previous year, appoints BLS as the exclusive manufacturer for NectarTek’s products in Australia, the UK, and Germany, enhancing Bioxyne’s market position and potential for future contracts.
Bioxyne Limited has announced the issuance of 115,600,000 shares at $0.025 per share as part of a capital raise, in accordance with the Corporations Act. This move, approved by the Board, complies with relevant legal provisions and signifies a strategic effort to bolster the company’s financial standing.
Bioxyne Limited has announced the quotation of 115,600,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of March 27, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations, which could positively impact its stakeholders and industry positioning.
Bioxyne Limited has requested a trading halt on its securities as it undertakes a bookbuild related to a capital raising effort. This move is aimed at ensuring an orderly market and will last until the company releases an announcement or until the start of normal trading on 21 March 2025. The trading halt is a strategic step in Bioxyne’s capital management, potentially impacting its financial positioning and stakeholder interests.